Serum Albumin, but not Bilirubin, is Associated with Diabetic Chronic Vascular Complications in a Chinese Type 2 Diabetic Population

Yu Zhu, Xiaoling Cai, Yan Liu, Mengdie Hu, Lingli Zhou, Wei Liu, Jing Wu, Rui Zhang, Xueying Gao, Wenjia Yang, Simin Zhang, Siqian Gong, Yingying Luo, Meng Li, Leili Gao, Ling Chen, Jing Chen, Xiuting Huang, Qian Ren, Xiuying Zhang, Xianghai Zhou, Xueyao Han & Linong Ji

To identify the factors associated with serum total bilirubin (STB) and determine whether STB is independently associated with diabetic retinopathy (DR) or diabetic kidney disease (DKD), 1,665 Chinese patients with type 2 diabetes (T2DM) (248 outpatients newly diagnosed with T2DM [NDM] and 1,417 inpatients previously diagnosed with T2DM [PDM]) were studied. Clinical and biochemical information was collected, and a single nucleotide polymorphism (rs6704078) of the UGT1A1 gene was genotyped in 1,059 individuals. Multiple linear regression showed that STB was associated with haemoglobin concentration, platelet count, and serum triglyceride concentration in NDM and PDM patients, and with serum albumin, duration of diabetes, and smoking in PDM patients. In patients with PDM, multiple logistic regression revealed that serum albumin was associated with DR (odds ratio [OR] = 0.92, 95% confidence interval [CI]: 0.87–0.96, \( p = 0.001 \)) and DKD (OR = 0.93, 95% CI: 0.88–0.98, \( p = 0.005 \)) after adjustment for STB, STB-related factors, and risk factors for DR and DKD. In addition, patients with the T allele of rs6704078 had higher STB (13.2 [10.4–17.9] \( \mu \text{mol/L} \) versus 11.8 [9.4–14.8] \( \mu \text{mol/L} \); \( p < 0.001 \)) and similar risks of DR or DKD to those without the T allele. Thus, serum albumin, but not STB, is associated with DR and DKD.

During recent decades, accumulating evidence has indicated that both oxidative stress and chronic inflammation are important in the development of type 2 diabetes (T2DM) and its chronic complications, including diabetic retinopathy (DR) and diabetic kidney disease (DKD). The total serum concentration of bilirubin, a physiologic antioxidant, has recently been reported to be associated with the risks of cardiovascular disease, diabetes and diabetic chronic vascular complications in a number of cross-sectional and observational studies, but Mendelian randomization studies have not supported a causal relationship between STB and stroke and coronary heart disease (CHD). Therefore, it is likely that unknown or unquantifiable confounders explain the association of serum total bilirubin (STB) with vascular complications observed in the previous studies, rather than STB itself.

Perhaps significantly, in addition to moderate hyperbilirubinemia, higher haemoglobin concentrations and low platelet counts characterize patients with Gilbert syndrome, and patients with this syndrome have also been reported to have low risks of cardiovascular disease and diabetes. It remains to be determined whether the relationship between STB and cardiovascular disease depends on haemoglobin concentration or platelet count in this syndrome. However, some case-control studies have shown that low haemoglobin concentration is associated with a higher risk of diabetic retinopathy, high platelet count and activity are well-known risk factors for cardiovascular disease, and anti-platelet drugs have been widely used for the prevention of cardiovascular disease. Therefore, it is necessary to adjust for these confounders when evaluating the relationship between STB and diabetic vascular disease.

Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Centre, Beijing, 100044, China. Yu Zhu and Xiaoling Cai contributed equally. Correspondence and requests for materials should be addressed to X.H. (email: xueyaohan@sina.com) or L.J. (email: jiln@bjmu.edu.cn)
However, the significance of STB-related factors has not been established in patients with T2DM, and in all the previous studies of the relationship between STB and vascular diseases, a number of the potential confounders, such as haemoglobin concentration and platelet count, have not been adjusted for. Therefore, we aimed to evaluate the relationships between STB and the prevalences of DR and DKD, while accounting for the effects of haemoglobin concentration, platelet count, and other blood parameters, in a Chinese population with T2DM.

**Methods**

**Ethics statement.** This study was performed in accordance with the tenets of the Declaration of Helsinki and approved by the ethics committee of Peking University People's Hospital (authorization numbers 2013-12 and 2010-71). Written informed consent was obtained from all the participants.

**Study population.** *Patients with newly diagnosed T2DM (NDM).* Between August 2014 and May 2018, a total of 248 patients with NDM were consecutively recruited in the Outpatient Clinic of the Department of Endocrinology and Metabolism, Peking University People's Hospital. These patients had never previously been treated using antidiabetic drugs or lifestyle interventions. This sample was recruited to determine the associations between STB and other blood parameters, to avoid the confounding effects of the use of hypoglycaemic agents and the duration of diabetes. Blood and urine samples were obtained before these patients began treatment for diabetes. Their clinical characteristics are summarized in Table 1.

*Patients with previously diagnosed T2DM (PDM).* A total of 1,417 consecutive inpatients with T2DM who were hospitalized at the Department of Endocrinology and Metabolism, Peking University People's Hospital, between 2011 and 2017, were enrolled in this study. All the patients had been taking hypoglycaemic agents before hospitalization. This sample was used to validate the findings obtained in the NDM population and assess the relationships of STB and related parameters with diabetic chronic vascular complications. Their clinical characteristics are summarized in Table 1.

**Inclusion and exclusion criteria.** All the participants were of Chinese Han origin and had been diagnosed with T2DM by diabetologists. Participants with a fasting plasma glucose (FPG) below 7 mmol/l and glycated haemoglobin (HbA1c) below 6.5% undertook a 75-g oral glucose tolerance test (OGTT). Diabetes was diagnosed according to World Health Organization criteria, on the basis of an FPG ≥7.0 mmol/l, a 2-h plasma glucose during the OGTT ≥11.1 mmol/l, and/or HbA1c ≥6.5%. Individuals were excluded if they had typical clinical features of type 1 diabetes (severe insulin deficiency [fasting serum C peptide <0.1 ng/ml] or dependency on insulin treatment within 2 years of a diagnosis of diabetes); had another specific form of diabetes, such as diabetes secondary to chronic pancreatitis or steroid treatment; were positive for glutamic acid decarboxylase, islet cell, and insulin autoantibody; had abnormal red or white blood cells in their urine, or other kidney disease, such as urolithiasis; had cancer, infection, acute diabetic complications, autoimmune disease, a blood disease, or obstructive jaundice; had high serum alanine transaminase (ALT) activity (>twice the upper limit of the normal range); had a white blood cell count <3.5 × 10^9/L, haemoglobin concentration <110 g/l in women and <120 g/l in men, or platelet count <10 × 10^9/L; or had a severe chronic liver disease, such as cirrhosis, viral hepatitis, or chronic alcohol-induced liver dysfunction.

**Biochemical measurements and clinical information.** The sex, age, duration of diabetes, smoking history, and presence of comorbidities or complications were recorded for each participant. The participants’ height, body mass, body mass index (BMI), waist circumference, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured.

After an overnight fast of 8–10 h, venous blood was collected for the measurement of FPG, total cholesterol, high-density lipoprotein-cholesterol (HDL-c), low-density lipoprotein-cholesterol (LDL-c), triglycerides (TG), creatinine, uric acid, STB, albumin, high-sensitivity C-reactive protein (only for NDM patients), and alanine transaminase and aspartate aminotransferase activities, using a Hitachi LST008 analyser. HbA1c was measured using high-performance liquid chromatography (Ultra2 HbA1c Detector, Primus Corporation, Atlanta, GA, USA). Roche C311 was used to measure the urinary albumin/creatinine ratio (UACR). White blood cell count, red blood cell count, haemoglobin concentration and platelet count were measured using a haematology analyser.

In our study, DKD was defined by a UACR ≥30 mg/g and/or renal insufficiency. A diagnosis of DR was made on the basis of direct ophthalmoscopy, fundic camera (TRC-NW100) examination or a history of laser photocoagulation therapy. CHD was diagnosed using the patients’ medical history (presence of angina or myocardial infarction and the results of computed tomography or coronary angiography). Cerebrovascular disease (CVD) was defined by a history of transient ischaemic attack, or ischaemic or haemorrhagic stroke. Hypertension was defined by a SBP ≥140 mmHg, a DBP ≥90 mmHg and/or current treatment for hypertension. Dyslipidaemia was defined by a total cholesterol ≥5.18 mmol/l, triglycerides ≥1.70 mmol/l, LDL-c ≥3.37 mmol/l, HDL-c <1.3 mmol/l in women or HDL-c <1.04 mmol/l in men, or treatment with anti-hyperlipidaemic agents. Peripheral arterial disease (PAD) was identified using ultrasonography; if plaques were detected in the carotid artery or the arteries of the lower extremities, a diagnosis of peripheral vascular atherosclerosis was made.

Blood and urinary biochemical data, and diagnoses of PAD, DR, DKD, hypertension or dyslipidaemia were collected from the participants’ medical records, and the presence of CHD or CVD and smoking status were self-reported.

**Study of the association between the UDP-glucuronyl transferase (UGT1A1) gene polymorphism and fasting STB.** DNA samples obtained from whole blood were available from 1,059 patients with T2DM, because some patients did not agree to provide samples or their samples had been exhausted. The rs6742078 single nucleotide polymorphism (SNP), which has previously been reported to be associated with STB...
and to explain more of the variation in STB than other SNPs, was genotyped by DNA sequencing or using a TaqMan SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA). For quality control, 5% of the samples were re-genotyped in a blinded fashion by DNA sequencing.

### Statistical analysis

Statistical analysis was performed using SPSS for Windows, v. 23.0 (IBM, Inc., Armonk, NY, USA). Normally distributed continuous data are presented as means and standard deviations (±SD) and non-normally distributed data are presented as medians (inter quartile range, IQR). Categorical variables are presented as numbers and percentages. The duration of diabetes, serum HDL-c, triglycerides, STB, creatinine, UACR, urine acid, alanine transaminase, aspartate aminotransferase and FPG were subjected to natural logarithmic transformation to obtain normally distributed data, prior to statistical analysis. Independent t-tests were performed to compare the means of two groups. If the data were not normally distributed, the Mann-Whitney U test was used as an alternative. The chi-square test was applied to compare the counts of categorical variables between groups. A p-value of < 0.05 was considered statistically significant.

### Table 1. Clinical characteristics of outpatients with newly diagnosed type 2 diabetes (NDM) and inpatients with previously diagnosed type 2 diabetes (PDM). Values are mean ± SD, median (interquartile range), or n (%).

| Characteristic                  | The clinical characteristics | NDM (n = 248) | PDM (n = 1417) |
|---------------------------------|------------------------------|--------------|-------------|
| Men/women, n                   | 150/98                       | 923/494      |
| Age, years                      | 49 ± 11                      | 54 ± 13      |
| Duration, years                 | —                            | 10 (4–15)    |
| BMI, kg/m²                      | 27.5 ± 4.0                   | 26.1 ± 3.9   |
| WC for female, cm               | 91 ± 9                       | 93 ± 11      |
| WC for male, cm                 | 96 ± 11                      | 96 ± 11      |
| SBP, mmHg                       | 128 ± 16                     | 130 ± 17     |
| DBP, mmHg                       | 81 ± 9                       | 79 ± 11      |
| FPG, mmol/l                     | 8.5 (7.2–11.3)               | 7.2 (5.8–8.9) |
| HbA1c, %                        | 9.0 ± 2.2                    | 9.3 ± 2.4    |
| TC, mmol/l                      | 5.2 ± 1.2                    | 4.5 ± 1.1    |
| TG, mmol/l                      | 1.9 (1.3–2.7)                | 1.6 (1.1–2.4) |
| HDL-c for female, mmol/l        | 1.15 (1.04–1.37)             | 1.05 (0.90–1.21) |
| HDL-c for male, mmol/l          | 1.03 (0.91–1.17)             | 0.90 (0.78–1.04) |
| LDL-c, mmol/l                   | 3.0 ± 0.9                    | 2.5 ± 0.8    |
| ALT, u/l                        | 29 (20–43)                   | 19 (14–30)   |
| AST, u/l                        | 22 (17–29)                   | 18 (15–24)   |
| ALB, g/l                        | 46.0 ± 2.7                   | 40.5 ± 3.2   |
| T-BIL, µmol/l                   | 12.7 (10.3–16.2)             | 11.7 (9.2–14.6) |
| CRE, µmol/l                     | 64 (53–75)                   | 64 (54–74)   |
| UA for female, µmol/l           | 316.0 (261.0–358.0)          | 308.0 (261.0–369.0) |
| UA for male, µmol/l             | 351.0 (309.8–421.8)          | 363.0 (306.0–425.8) |
| High-sensitivity CRP, mg/l      | 2.4 (1.3–4.5)                | —            |
| UACR, mg/g                      | 10.1 (5.2–22.4)              | 6.6 (2.9–21.8) |
| WBC, 10⁹/l                      | 7.16 ± 2.2                   | 6.6 ± 1.6    |
| RBC, 10¹²/l                     | 5.1 ± 0.5                    | 4.5 ± 0.5    |
| Hb, g/dl                        | 15.1 ± 1.4                   | 13.8 ± 1.3   |
| PLT, 10⁹/dl                     | 244 ± 5.9                    | 19.9 ± 5.0   |
| Smoking, n (%)                  | 84 (33.9)                    | 639 (45.1)   |
| Hypertension, n (%)             | 90 (36.3)                    | 720 (50.8)   |
| Dyslipidemia, n (%)             | 172 (69.4)                   | 1011 (71.3)  |
| CHD, n (%)                      | 10 (4.0)                     | 196 (13.8)   |
| CVD, n (%)                      | 5 (2.0)                      | 178 (12.6)   |
| PAD, n (%)                      | 115 (45.6)                   | 1221 (86.2)  |
| DR, n (%)                       | 16 (6.5)                     | 297 (20.9)   |
| DKD, n (%)                      | 45 (18.1)                    | 256 (18.2)   |
LDL-c: low-density lipoprotein-cholesterol; ALT, alanine transaminase. ALB, serum albumin; T-BIL, total bilirubin; WBC, white blood cell count; RBC, red blood cell count; Hb, haemoglobin concentration; UACR, urinary albumin-to-creatinine ratio.

Table 2. Multiple logistic regression analysis of the relationships between diabetic retinopathy or diabetes kidney disease and serum bilirubin in inpatients with previously diagnosed type 2 diabetes (PDM). WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; ALB, serum albumin; T-BIL, total bilirubin; WBC, white blood cell count; RBC, red blood cell count; Hb, haemoglobin concentration; PLT, platelet count; TG, triglycerides; HDL-c, high-density lipoprotein-cholesterol; LDL-c, low-density lipoprotein-cholesterol; ALT, alanine transaminase.

|                      | DR                                      | DKD                                      |
|----------------------|-----------------------------------------|------------------------------------------|
|                      | B (OR [95% CI])                          | P                                        | B (OR [95% CI])                          | P                                        |
| Female               | 0.017 (1.02(0.65–1.59)                  | 0.940                                    | −0.482                                  | 0.62(0.38–1.01)                          | 0.057                                   |
| Age, years           | −0.031 (0.97(0.95–0.97)                 | <0.001                                   | −0.02                                   | 0.96(0.96–0.99)                          | 0.033                                   |
| Duration, years      | 0.092 (1.10(1.07–1.12)                 | <0.001                                   | 0.073                                   | 1.08(1.05–1.10)                          | <0.001                                  |
| BMI, kg/m²            | −0.052 (0.95(0.88–1.02)                | 0.156                                    | 0.012                                   | 1.01(0.94–1.09)                          | 0.761                                   |
| WC, cm               | 0.021 (1.02(0.99–1.05)                 | 0.116                                    | 0.011                                   | 1.01(0.98–1.04)                          | 0.420                                   |
| ALT, u/l             | −0.007 (0.99(0.93–1.01)                | 0.181                                    | −0.010                                  | 0.99(0.98–1.01)                          | 0.088                                   |
| FPG, mmol/l          | 0.091 (1.09(1.03–1.16)                 | 0.003                                    | 0.082                                   | 1.09(1.01–1.16)                          | 0.019                                   |
| HbA1c, %             | 0.033 (1.03(0.97–1.10)                 | 0.295                                    | −0.002                                  | 0.99(0.92–1.08)                          | 0.966                                   |
| Hb, g/dl             | −0.129 (0.88(0.76–1.02)                | 0.090                                    | −0.147                                  | 0.86(0.74–1.01)                          | 0.070                                   |
| Alb, g/l             | −0.086 (0.92(0.87–0.96)                | 0.001                                    | −0.075                                  | 0.93(0.88–0.98)                          | 0.005                                   |
| PLT, 10⁹/dl          | −0.027 (0.97(0.94–1.01)                | 0.115                                    | −0.024                                  | 0.97(0.94–1.01)                          | 0.191                                   |
| T-Bil, μmol/l        | −0.023 (0.98(0.94–1.01)                | 0.202                                    | −0.016                                  | 0.98(0.93–1.02)                          | 0.598                                   |
| WBC, 10⁹/l           | 0.058 (1.06(0.96–1.17)                 | 0.243                                    | 0.238                                   | 1.27(1.15–1.40)                          | <0.001                                  |
| TG, mmol/l           | −0.017 (0.98(0.92–1.06)                | 0.640                                    | 0.066                                   | 1.07(1.01–1.14)                          | 0.035                                   |
| LDL-c, mmol/l        | 0.051 (1.05(0.87–1.27)                 | 0.595                                    | 0.014                                   | 1.01(0.83–1.24)                          | 0.894                                   |
| HDL-c, mmol/l        | −0.321 (0.73(0.42–1.24)                | 0.243                                    | 0.206                                   | 1.23(0.84–1.80)                          | 0.294                                   |
| SBP, mmHg            | 0.019 (1.02(1.01–1.03)                 | 0.002                                    | 0.019                                   | 1.02(1.01–1.03)                          | 0.003                                   |
| DBP, mmHg            | −0.014 (0.99(0.97–1.01)                | 0.119                                    | −0.006                                  | 0.99(0.98–1.01)                          | 0.508                                   |
| Hypertension         | 0.246 (1.28(0.90–1.81)                 | 0.164                                    | 0.960                                   | 2.61(1.78–3.84)                          | <0.001                                  |
| Dyslipidemia         | 0.024 (1.02(0.74–1.43)                 | 0.888                                    | −0.088                                  | 0.92(0.64–1.32)                          | 0.634                                   |
| Smoking              | 0.02 (0.92(0.71–1.48)                  | 0.92                                     | 0.136                                   | 1.15(0.77–1.70)                          | 0.497                                   |

The associations of STB and related factors with diabetic chronic vascular complications were evaluated in patients with PDM. Multiple logistic regression analysis (Table 2) was conducted with DR or DKD as the dependent variable, and sex, age, duration of diabetes, BMI, waist circumference, FPG, HbA1c, SBP, DBP, serum albumin, alanine transaminase, STB, triglycerides, HDL-c, LDL-c, white blood cell count, haemoglobin concentration; PLT, platelet count; TG, triglycerides; HDL-c, high-density lipoprotein-cholesterol; LDL-c, low-density lipoprotein-cholesterol; ALT, alanine transaminase.

Results

Relationships between serum bilirubin and other blood and urine parameters in patients with NDM or PDM. In the participants with NDM, in whom there was no confounding by the use hypoglycaemic agents or the duration of diabetes, multiple linear regression analysis was conducted with ln-transformed STB as the dependent variable, and sex, age, BMI, waist circumference, FPG, HbA1c, SBP, DBP, serum albumin, triglycerides, HDL-c, LDL-c, serum creatinine, UACR, white blood cell count, haemoglobin concentration, platelet count, and smoking status as independent variables. A logistic regression analysis with a forward method was also performed with DR or DKD as the dependent variable, and sex, age, BMI, waist circumference, FPG, HbA1c, SBP, DBP, STB, serum albumin, triglycerides, HDL-c, LDL-c, white blood cell count, haemoglobin concentration, platelet count, smoking, hypertension and dyslipidaemia as independent variables. P < 0.05 was considered to represent statistical significance.

Relationships of STB and related parameters with diabetic chronic vascular complications. The associations of STB and related factors with diabetic chronic vascular complications were evaluated in patients with PDM. Multiple logistic regression analysis was conducted with DR or DKD as the dependent variable, and sex, age, duration of diabetes, BMI, waist circumference, FPG, HbA1c, SBP, DBP, serum albumin, alanine transaminase, STB, triglycerides, HDL-c, LDL-c, white blood cell count, haemoglobin concentration, platelet count, smoking, hypertension and dyslipidaemia as independent variables. P < 0.05 was considered to represent statistical significance.
concentration, platelet count and smoking status as independent variables. The results showed that age, duration of diabetes, FPG, serum albumin and SBP were independently associated with DR, and that age, duration of diabetes, FPG, serum albumin, triglycerides, SBP, hypertension and white blood cell count were independently associated with DKD. After excluding 30 patients who had UACR > 1,000 mg/g, the associations between serum albumin and DKD or DR remained significant.

The relationship between the UGT1A1 gene polymorphism and fasting STB. A total of 1,059 participants with NDM or PDM were genotyped for rs6742078. The frequencies of the three genotypes (GG, GT and TT) were 75.5%, 21.0% and 1.5%, respectively. The frequencies of the G and T alleles were 88.0% and 12.0%, respectively, which are very similar to those (89% and 11%) recorded for the Chinese Han population in the 1,000-genome database (http://phase3browser.1000genomes.org/index.html). The genotype distribution was in Hardy-Weinberg equilibrium (calculated using software at http://www.ocege.org/software/hwe-mr-calc.html). As shown in Table 3, the STB in patients with the GG genotype was lower than that of those with GT or TT genotypes. Multiple linear regression analysis showed that STB was associated with the T allele under the dominant model, after adjustment for sex, age, BMI, waist circumference, FPG, HbA1c, SBP, DBP, serum albumin, alanine transaminase, triglycerides, HDL-c, LDL-c, creatinine, UACR, white blood cell count, haemoglobin concentration, platelet count and smoking status. However, the prevalence of DR, DKD, CHD, CVD, PVD, hypertension and dyslipidaemia were similar in participants with the GG and GT/TT genotypes. The T allele was not associated with DR (odds ratio [OR] = 0.94, 95% confidence interval [CI]: 0.68–1.31, p = 0.72) or DKD (OR = 0.87, 95% CI: 0.62–1.23, p = 0.44) in logistic regression analysis.

Discussion
In this study, we have found that STB is positively associated with haemoglobin concentration and serum albumin, and negatively with platelet count. However, serum albumin concentration, but not STB, was independently associated with DR and DKD. We have also replicated previous findings that the T allele of rs6742078 is independently associated with STB, but the prevalence of DR and DKD in patients with the T allele was similar to those without it, meaning that no association between DR or DKD and the T allele was identified.

Senescent or damaged red blood cells are degraded and release haem, which is broken down by haem oxygenase, generating biliverdin and carbon monoxide. Biliverdin reductase then reduces biliverdin to bilirubin. Through these mechanisms, cells are protected against haem accumulation. Bilirubin binds to plasma albumin, is transported to the liver and conjugated by UGT1A139. Thus, it is not surprising that we found that STB is associated with haemoglobin concentration and red blood cell count, because these variables are directly related to the number of senescent red blood cells.

Because bilirubin binds to plasma albumin and is transported to the liver, and the concentration of free bilirubin in the plasma is normally very low (<0.01%)39, its concentration is substantially affected by the plasma albumin concentration. Hypertriglyceridaemia is a component of the metabolic syndrome characterised by central obesity, insulin resistance, chronic low-grade inflammation, hyperglycaemia, dyslipidaemia and hypertension1,2. In individuals with the metabolic syndrome, haem oxygenase is induced during oxidative stress and inflammation, which might lead to greater production of bilirubin21. Similarly, cigarette smoke can induce oxidative stress, with the same potential consequence22. However, once haem oxygenase is induced, the oxidative stress and inflammation should be ameliorated, which could help prevent platelet overactivity. Consistent with this, a patient with haem oxygenase-1 deficiency presented with thrombocytosis and lower bilirubin production23. Moreover, inhibition of haem oxygenase activity limits the production of bilirubin and enhances 15d-prostaglandin concentration39. It is likely that serum bilirubin bound to albumin only provides minor protection against oxidative stress, because the associations between serum albumin and diabetic chronic vascular complications would have been lost if confounders such as haemoglobin and albumin had been adjusted for. Furthermore, we now show that STB is not associated with DR or DKD after these covariates are adjusted for. Because the liver has a remarkable ability for compensation and most patients with DKD are not macroalbuminuric, the associations between serum albumin and DR or DKD cannot be explained by the loss of albumin through the kidneys alone. Thus, we are confident that the observed associations between serum albumin and diabetic chronic vascular complications are real.

Albumin is synthesized in the liver and accounts for more than half of serum protein. Serum albumin has many physiological functions, including the transport of inorganic ions, fatty acids, bilirubin, hormones and drugs. In addition, it contains abundant thiol groups that can scavenger most of the reactive oxygen in the blood37. Low serum albumin concentration is associated with ischemic heart disease, heart failure, atrial fibrillation, stroke, venous thromboembolism, atherosclerosis, end-stage renal disease and inflammation, which is consistent with the antioxidant, anti-inflammatory, anticoagulant and anti-platelet aggregation activities of the protein37,38. Many factors can reduce albumin synthesis, including malnutrition, inflammation, diabetes, liver disease and sepsis; and greater catabolism, vascular permeability and renal or enteric loss can also lead to low serum albumin concentration39. It is likely that serum bilirubin bound to albumin only provides minor protection against oxidative stress, because the associations between STB and DR or DKD disappeared when serum albumin concentration was adjusted for in the present study. This implies that serum albumin might contribute to the development of diabetic chronic vascular complications through its antioxidant, anti-inflammatory and anticoagulant effects.
To identify a potential causal relationship between bilirubin and cardiovascular disease, several studies have been conducted using Mendelian randomization analysis. In a Korean cohort of 4,793 healthy subjects and 806 stroke patients, both the rs6742078 SNP and the weighted genetic risk score at the UGT1A1 locus were shown to be associated with STB, but no evidence was presented showing that serum bilirubin is causally associated with stroke risk. Another large study of 67,068 individuals in three cohorts showed that STB is not causally associated with the risk of ischemic heart disease, within each cohort and in a meta-analysis.

However, to date, a Mendelian randomization study has not been conducted of the relationships between STB and DR or DKD. In the present study, we genotyped 1,059 patients with T2DM and did not identify an association between rs6742078 and diabetic microvascular complications (DR or DKD) or the well-established risk factors for cardiovascular disease, implying no causal association of STB with DR or DKD. Instead, it may be that the associations between STB and chronic diabetic complications identified in previous studies might be due to greater activity of haem oxygenase, because the oxidative stress and inflammation present in patients with diabetes, which are related to serum albumin concentration, may activate haem oxygenase. Haem oxygenase protects cells by degrading haem and generating carbon monoxide, rather than the by-product of bilirubin, and the association between the highly expressed allele of the haem oxygenase gene and low vascular disease risk.

Table 3. Clinical characteristics of patients with differing UGT1A1 genotype. Values are mean ± SD, median (interquartile range), or n (%). WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALB, serum albumin; T-BIL, total bilirubin; CRE, creatinine; UA, uric acid; TC, total cholesterol; TG, triglycerides; HDL-c, high-density lipoprotein-cholesterol; LDL-c, low-density lipoprotein-cholesterol; ALT, alanine transaminase; UACR, urine albumin-creatinine ratio; WBC, white blood cell count; RBC, red blood cell count; Hb, haemoglobin concentration; PLT, platelet count; CHD, coronary heart disease; PAD, peripheral arterial disease; CVD, cerebral vascular disease; DR, diabetic retinopathy; DKD, diabetic kidney disease.
supports the hypothesis that STB represents a marker of the production of bilirubin within tissues, rather than a key mediator of vascular disease. In the present study, we have found that STB is not associated with DR or DKD after adjustment for confounders (haemoglobin concentration, platelet count and serum albumin) but that serum albumin is. These findings are consistent with the results of previous Mendelian randomization studies. Although there has been no previous Mendelian randomization study regarding the association of STB with chronic vascular complications, we hypothesise that bilirubin is not important in the development of DR or DKD because the pathogenesis of diabetic microvascular disease and microvascular disease of other aetiologies is similar, involving oxidative stress and inflammation. Mendelian randomization studies are useful for the identification of causal relationships between associated factors, and in the present study we found that a representative SNP in UGT1A1 is not associated with diabetic vascular complications or the well-established risk factors for vascular disease, suggesting that bilirubin might not play an important role in the development of DR and DKD.

There were some limitations to this study. Firstly, the sample size of the genetic association study was not large enough to evaluate the relationship between an allele with a small effect and diabetic chronic vascular complications. The study described had enough power (>0.8) only for an allele with an odds ratio >1.46 in a dominant genetic model, when the prevalence of DKD was 0.2 in a T2DM population and the T allele frequency was 0.12 (http://zzz.bwh.harvard.edu/cgi-bin/cc2k.cgi). Therefore, a large Mendelian randomization study should be conducted in the future that involves multiple SNPs, to help clarify whether any causal relationship between STB and diabetic vascular complications exists. In addition, because many covariates were adjusted for in the multiple logistic regression (Table 2), a further study with a larger sample size is needed to confirm our findings. Secondly, because the study was cross-sectional in nature, conclusions regarding causality must be corroborated by future longitudinal studies. It is possible that serum albumin is a marker of oxidative stress and inflammation in diabetic patients. Thirdly, a total of 1,059 patients were genotyped for rs6742078 because DNA samples were not available from all the patients, which might have led to bias. Compared with the participants as a whole, this sub-sample contained higher percentages of women and older people, and people with higher SBP, TG and STB concentrations, lower LDL–c, HbA1c and shorter duration of diabetes (data not shown). However, these differences between the sub-sample and the full cohort may not have a large impact on the results of the association study of rs6742078 with STB, DR and DKD because the frequencies of the G and T alleles at rs6742078 were very similar to those stated for Chinese people in the 1,000-genome database (12% vs. 11%), the distribution of rs6742078 genotypes was in accordance with Hardy-Weinberg equilibrium, and except for STB, the other clinical features were similar between the people with GG and those with GT/TT genotypes.

In summary, serum bilirubin was associated with haemoglobin concentration, platelet count, serum albumin, triglycerides, duration of diabetes and smoking status in a Han Chinese population with T2DM. Serum albumin, but not bilirubin, was independently associated with DR and DKD. Thus, serum bilirubin may not contribute significantly to the development of diabetic chronic vascular complications.

Data Availability
The data are available on request from the authors.

References
1. Jha, J. C., Ho, F., Dan, C. & Jandeleit-Dahm, K. A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. Clin Sci (Lond) 132, 1811–1836 (2017).
2. Yaribeygi, H., Atkin, S. L. & Sahebkar, A. A review of the molecular mechanisms of hyperglycemia-induced free radical generation leading to oxidative stress. J Cell Physiol, https://doi.org/10.1002/jcp.27164 (2018).
3. Ferrucci, L. & Fabбри, E. Inflammaging: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 15, 505–522 (2018).
4. Djousse, L. et al. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. The American journal of cardiology 87, 1196–1200 (2001).
5. Song, Y. S., Koo, B. K., Cho, N. H. & Moon, M. K. Effect of low serum total bilirubin levels (≤0.32 mg/dl) on risk of coronary artery disease in patients with metabolic syndrome. The American journal of cardiology 114, 1695–1700 (2014).
6. Kimm, H., Yun, J. E., Jo, J. & Jee, S. H. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 40, 3422–3427 (2009).
7. Chan, K. H. et al. Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 56, 724–736 (2013).
8. Abbasi, A. et al. Bilirubin as a potential causal factor in type 2 diabetes risk: a Mendelian randomization study. Diabetes 64, 1459–1469 (2015).
9. Hamamoto, S. et al. Low bilirubin levels are an independent risk factor for diabetic retinopathy and nephropathy in Japanese patients with type 2 diabetes. Diabetes Metab 41, 429–431 (2015).
10. Sekioka, R., Tanaka, M., Nishimura, T. & Itoh, H. Serum total bilirubin concentration is negatively associated with increasing severity of retinopathy in patients with type 2 diabetes mellitus. J Diabetes Complications 29, 218–221 (2015).
11. Zhu, B., Wu, X., Bi, Y. & Yang, Y. Effect of bilirubin concentration on the risk of diabetic complications: A meta-analysis of epidemiologic studies. Sci Rep 7, 41681 (2017).
12. Lee, S. J. et al. Bilirubin and Stroke Risk Using a Mendelian Randomization Design. Stroke 48, 1154–1160 (2017).
13. McArdle, P. F. et al. Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference. BMC Cardiovasc Disord 12, 16 (2012).
14. Stender, S., Frikke-Schmidt, R., Nordestgaard, B. G., Grande, P. & Tybjærg-Hansen, A. Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis. J Intern Med 273, 59–68 (2013).
15. Cire, M. C., Cure, E., Kurbas, A., Cicak, A. C. & Yuce, S. The effects of Gilbert’s syndrome on the mean platelet volume and other hematological parameters. Blood Coagul Fibrinolysis 24, 484–488 (2013).
16. Vitek, L. et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 160, 449–456 (2002).
17. Conway, B. N., Miller, R. G., Klein, R. & Orchard, T. J. Prediction of proliferative diabetic retinopathy with hemoglobin level. Arch Ophthalmol 127, 1494–1499 (2009).
18. Grundy, S. M. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44, 720–732 (2004).
19. Fujisawa, R. et al. Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. Hepatology 67, 1609–1619 (2018).
20. Vitek, L. & Ostrow, J. D. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr Pharm Des 15, 2869–2883 (2009).
21. Abraham, N. G., Junge, J. M. & Drummond, G. S. Translational Significance of Heme Oxygenase in Obesity and Metabolic Syndrome. Trends Pharmacol Sci 37, 17–36 (2016).
22. Van Hoydonck, P. G., Temme, E. H. & Schouten, E. G. Serum bilirubin concentration in a Belgian population: the association with smoking status and type of cigarettes. International journal of epidemiology 30, 1465–1472 (2001).
23. Kawashima, A., Oda, Y., Yachie, A., Koizumi, S. & Nakashima, I. Heme oxygenase-1 deficiency: the first autopsy case. Hum Pathol 33, 125–130 (2002).
24. O’Brien, J. J. et al. 15-deoxy-Delta12,14 prostaglandin J2-induced heme oxygenase-1 in megakaryocytes regulates thrombopoiesis. J Thromb Haemost 7, 182–189 (2009).
25. Gazzin, S., Vitek, L., Watchko, J., Shapiro, S. M. & Tiribelli, C. A Novel Perspective on the Biology of Bilirubin in Health and Disease. Trends Mol Med 22, 758–768 (2016).
26. Lee, M. K. et al. High hemoglobin levels are associated with decreased risk of diabetic retinopathy in Korean type 2 diabetes. Sci Rep 8, 5538 (2018).
27. Ito, H. et al. Mild anemia is frequent and associated with micro- and macroangiopathies in patients with type 2 diabetes mellitus. J Diabetes Investig 1, 273–278 (2010).
28. Qiao, Q., Keinanen-Kiukaanniemi, S. & Liäärä, E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol 50, 153–158 (1997).
29. Williams, A. N. & Conway, B. N. Effect of high density lipoprotein cholesterol on the relationship of serum iron and hemoglobin with kidney function in diabetes. J Diabetes Complications 31, 958–963 (2017).
30. Tsai, M. H., Leu, J. G., Fang, Y. W. & Liou, H. H. High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4. Medicine (Baltimore) 95, e5049 (2016).
31. Kawai, Y. et al. Association between serum albumin level and incidence of end-stage renal disease in patients with Immunglobulin A nephropathy: A possible role of serum albumin as an antioxidant agent. PLoS One 13, e0196655 (2018).
32. Iwasaki, A., Oda, Y., Yachie, A., Koizumi, S. & Nakanishi, I. Heme oxygenase-1 deficiency: the first autopsy case.
33. Grundy, S. M. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44, 720–732 (2004).
34. Williams, A. N. & Conway, B. N. Effect of high density lipoprotein cholesterol on the relationship of serum iron and hemoglobin with kidney function in diabetes. J Diabetes Complications 31, 958–963 (2017).
35. Tsai, M. H., Leu, J. G., Fang, Y. W. & Liou, H. H. High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4. Medicine (Baltimore) 95, e5049 (2016).
36. Iwasaki, A., Oda, Y., Yachie, A., Koizumi, S. & Nakanishi, I. Heme oxygenase-1 deficiency: the first autopsy case.
37. Grundy, S. M. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44, 720–732 (2004).
38. Williams, A. N. & Conway, B. N. Effect of high density lipoprotein cholesterol on the relationship of serum iron and hemoglobin with kidney function in diabetes. J Diabetes Complications 31, 958–963 (2017).
39. Tsai, M. H., Leu, J. G., Fang, Y. W. & Liou, H. H. High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4. Medicine (Baltimore) 95, e5049 (2016).
40. Iwasaki, A., Oda, Y., Yachie, A., Koizumi, S. & Nakanishi, I. Heme oxygenase-1 deficiency: the first autopsy case.
41. Grundy, S. M. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44, 720–732 (2004).
42. Williams, A. N. & Conway, B. N. Effect of high density lipoprotein cholesterol on the relationship of serum iron and hemoglobin with kidney function in diabetes. J Diabetes Complications 31, 958–963 (2017).
43. Tsai, M. H., Leu, J. G., Fang, Y. W. & Liou, H. H. High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4. Medicine (Baltimore) 95, e5049 (2016).
44. Iwasaki, A., Oda, Y., Yachie, A., Koizumi, S. & Nakanishi, I. Heme oxygenase-1 deficiency: the first autopsy case.
45. Grundy, S. M. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44, 720–732 (2004).
46. Williams, A. N. & Conway, B. N. Effect of high density lipoprotein cholesterol on the relationship of serum iron and hemoglobin with kidney function in diabetes. J Diabetes Complications 31, 958–963 (2017).
47. Tsai, M. H., Leu, J. G., Fang, Y. W. & Liou, H. H. High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4. Medicine (Baltimore) 95, e5049 (2016).
48. Iwasaki, A., Oda, Y., Yachie, A., Koizumi, S. & Nakanishi, I. Heme oxygenase-1 deficiency: the first autopsy case.